Skip to main content

Evolva brings natural sugar blocker to market

| News

Evolva brings natural sugar blocker to market

21.01.2021

The biotech company Evolva is introducing L-arabinose to the market. This product is a natural sugar blocker and can be used both for healthy eating and as a reducing sugar in food processing.

Research and development in a laboratory of Evolva (img: Evolva)

Evolva, a biotech company headquartered in Reinach in the canton of Basel-Landschaft, has presented its new product L-arabinose, a natural sugar blocker. According to a press release, studies have demonstrated the effect of L-arabinose on adjusting to a healthy blood sugar level. The sugar blocker can also help with maintaining a healthy weight, for example by foregoing food and drink that contains a lot of sugar. L-arabinose is created by fermentation and is a good substitute for sugar in products such as yogurt, chocolate, soft drinks, ice cream, cereals, energy bars, and confectionary. The company’s press release states that its effect as a reducing sugar means that it can be used to create salty and savory chicken and beef flavors.

Oliver Walker, CEO of Evolva, is quoted as saying: “As people around the world continue to strive to live a healthier lifestyle, we are committed to helping our customers create healthier, more sustainable solutions. With this launch we are confirming our ability to deliver innovations that support human health and wellbeing.”

This new, natural sugar blocker is also of economic interest. Evolva has a current market volume of 250 million Swiss francs, and market growth of around 5 percent per year is anticipated. Evolva has revealed that marketing discussions are already underway with major clients.

Share this article

Sign up to receive our newsletter in your inbox.

You may also be interested in

Building the future of healthtech, digital health and techbio in the Basel Area

Meet our Chief Representative USA: with over 30 years in the biotech industry, Kirsten Detrick brings invaluable expertise for companies...
Read More

The power of a persuasive pitch deck

Are you an entrepreneur striving to secure investment for your biotech startup? Start with an effective pitch deck to catch...
Read More

Roche investing an additional 1.2 billion Swiss francs in Basel

Roche will be putting an additional 1.2 billion Swiss francs towards the renovation of its site in Basel. This investment...
Read More

Nouscom secures 67.5 million euros in financing

Biotech company Nouscom has raised 67.5 million euros in a series C financing round. The Basel-based firm intends to use...
Read More

Celebrating six months of innovation: i4Challenge accelerator New Ideas 2022/2023

On the 5th of July 2023, the 3rd iteration of the i4Challenge accelerator program New Ideas came to its conclusion....
Read More

How open innovation in healthtech hubs is fueling the rise of digital healthcare

How the ever-increasing uptake of digital solutions is enhancing patient engagement, increasing access to care and lowering the cost of...
Read More

Do you have a question? We'd like to hear from you.